A centrally active drug that modulates AMPA receptor gated currents
References (5)
- et al.
A simple method for organotypic cultures oissue
J. Neurosci. Meth.
(1991) - et al.
Allosteric potentiation of quisqualate receptors by a nootropic drug anuractctam
J. Physiol.
(1990)
Cited by (115)
Drug Discovery for Targeted Pharmacotherapy of Fragile X Syndrome
2017, Fragile X Syndrome: From Genetics to Targeted TreatmentThe NMDA receptor as a target for cognitive enhancement
2013, NeuropharmacologyEssential role of protein kinase C in morphine-induced rewarding memory
2012, NeuropharmacologyCitation Excerpt :Chen and Huang (1991) demonstrated that a selective μ-opioid receptor agonist DAMGO caused a sustained increase in glutamate-activated currents that were mediated by NMDARs, and this increase was PKC dependent (Chen and Huang, 1991), so it is reasonable to speculate that NR2B may be one of the downstream substrates of PKC when it is activated via morphine, and the change of PKC activity may be result from the morphine-associated learning but not the only pharmacological effect of morphine. It has been reported that inhibition of PKC activity decreases morphine-induced c-Fos expression in the striatum (Harlan et al., 2004), and the c-Fos expression in the striatum is also dependent on AMPA receptors (Arai et al., 1994) and mGluR1 (Moroni et al., 1997). Interestingly, both AMPA receptors and mGluR1 mediated, morphine-induced c-Fos expression is PKC activity-mediated (Garcia et al., 2003).
A novel class of allosteric modulators of AMPA/Kainate receptors
2009, Bioorganic and Medicinal Chemistry Letters
This research was supported by a Grant from the AFOSR.
- 1
The authors wish to express their sincere thanks to Dr. C.-M. Tang for his technical advice concerning the construction of the fast-switching system and for providing various components for the setup. The author thank Jackie Porter and Marla Lay for their secretarial assistance.